RECRUITING

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

Description

This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

Conditions

Schizophrenia
Talk to us

Related Conditions:

Schizophrenia

Study Overview

On this page

Study Details

Study overview

This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

Condition
Schizophrenia
Intervention / Treatment

-

Contacts and Locations

Pico Rivera

Neurocrine Clinical Site, Pico Rivera, California, United States, 90660

San Diego

Neurocrine Clinical Site, San Diego, California, United States, 92123

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participant has a primary diagnosis of schizophrenia
  • * Participants taking prohibited medications, including antipsychotics, must discontinue before study participation
  • * Participant must reside in a stable housing situation
  • * Participant has known hypersensitivity to any component of the formulation of NBI-1117568
  • * Participant has an unstable or poorly controlled medical condition or chronic disease
  • * Participant is considered by the investigator to be at imminent risk of suicide or injury to self or others
  • * Participant has a diagnosis of moderate or severe substance use disorder (with the exception of nicotine or caffeine dependence) within 6 months prior to screening
  • * Participant has a positive alcohol test or drug screen for disallowed substances
  • * Participant has a history of poor or suspected poor compliance in clinical research studies and/or in the investigator's opinion, the participant is not capable of adhering to the protocol requirements.

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Neurocrine Biosciences,

Clinical Development Lead, STUDY_DIRECTOR, Neurocrine Biosciences

Study Record Dates

2031-12